CSL has priced US$1.5 billion of corporate bonds in the United States, turning to offshore debt markets to refinance its ...
An experimental treatment being developed by Syntara improved movement in people at high risk of developing Parkinson's disease, and the benefit held for three months after treatment stopped, ...
Seven leading Chinese medical societies have jointly published an expert consensus naming Technegas the preferred ventilation agent for lung imaging in pulmonary embolism, handing the Sydney ...
Perth-based company PYC Therapeutics will take early human data on its polycystic kidney disease drug to the American Society of Nephrology conference in Denver on 22 October.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results